4D pharma plc (DDDD.L)
| Previous close | 146.00 |
| Open | 139.50 |
| Bid | 137.00 x 0 |
| Ask | 137.50 x 0 |
| Day's range | 132.87 - 145.00 |
| 52-week range | 23.50 - 183.00 |
| Volume | 4,015,572 |
| Avg. volume | 2,275,567 |
| Market cap | 178.839M |
| Beta (5Y monthly) | 2.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -31.60 |
| Earnings date | 24 May 2021 - 28 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 400.00 |
- Business Wire
4D Pharma Announces U.S. SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that the United States Securities and Exchange Commission ("SEC") has declared effective its registration statements on Form F-4 with respect to the issuance of 4D pharma American Depositary Shares ("ADSs") to the shareholders of Longevity Acquisition Corporation (NASDAQ: LOAC) ("Longevity"), a NASDAQ-listed special purpose acquisition company ("SPAC"), in connection with the previously announced merger between 4D pharma and Longevity.
- Business Wire
4D Pharma to Participate in Upcoming Cantor Fitzgerald Microbiome Leaders Panel
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces Duncan Peyton, Chief Executive Officer of 4D pharma, will participate in Cantor Fitzgerald’s virtual panel, titled "Microbiome Players with Guided Readouts in 2021," on Thursday, February 18, 2021 at 15:00 GMT (10:00 ET).
- Business Wire
4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for BAVENCIO® (avelumab), the first and only immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma. BAVENCIO is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc.
